BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 25/10/2017

FDA Clears Way for Norgestrel Tablet Approval

The FDA has determined that the 0.075mg OVRETTE (norgestrel) tablet was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of the generic version.

Source: Federal Register — Food and Drug AdministrationOpen original release →